Product logins

Find logins to all Clarivate products below.


The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in anticancer treatment since the advent of the cytokines. Their approvals dramatically altered the treatment landscape in their respective indications—prostate cancer and malignant melanoma—and laid the foundations for the re-emergence of immunotherapy as a key treatment strategy in oncology. A plethora of cancer immunotherapies are in development for multiple oncology indications and present a highly lucrative opportunity for immunotherapy developers.

Related Market Assessment Reports

Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.4…
Report
Dry and Wet Age-Related Macular Degeneration | Special Topics | US | 2019
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Report
Postoperative Pain | Special Topics | US | 2020
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…
Report
Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…